Asahi Life Asset Management Co., Ltd. Bei Gene, Ltd. Transaction History

Asahi Life Asset Management Co., Ltd.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $150,933 - $215,928	-682 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$189.18 - $286.44 $129,020 - $195,352	682 New	682 $195,000
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $112,702 - $160,200	-925 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$115.78 - $208.34 $107,096 - $192,714	925 New	925 $153,000

233

41.5M

81.2K

82.4K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Asahi Life Asset Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Asahi Life Asset Management Co., Ltd. with notifications on news.